blog

Small Supplement Trial Reports Gains in Three Vascular Markers

STAMINA reported favorable vascular-marker changes in a small supplement trial. A closer look at the results, incomplete follow-up and evidence limits.

Small Supplement Trial Reports Gains in Three Vascular Markers
Share
PinterestFacebookLinkedInRedditTelegramX
Nov 12, 2026
Biological Age & Testing

On November 4, 2026, MedicalXpress reported on the University of Surrey's published STAMINA trial, which tested a multicomponent supplement over six months.

The main finding concerns vascular function

The STAMINA researchers reported favorable differences between the supplement and control groups in three vascular measurements: flow-mediated dilation, arterial stiffness and systolic blood pressure. The primary result concerned how an artery responds to increased blood flow. For longevity research, this is a preliminary signal about vascular function rather than evidence of reduced biological age or longer life. Its value lies in identifying a result that further research can test against meaningful health outcomes.

The trial tested a complete formulation in humans

Study type: A randomized trial in humans, not an in vitro experiment or an animal study.

According to the study details accompanying the MedicalXpress report, STAMINA was a randomized, double-blind controlled trial. Researchers assigned participants to a multicomponent supplement or a control and assessed vascular measurements over six months. The study randomized 61 people.

The relevant results were adjusted differences between the groups. They were not simply descriptions of how much the supplement group's measurements changed from their own starting values. That distinction matters when a headline compresses a controlled trial into a claim that a product “improved vascular health.”

An adjusted between-group difference describes the contrast estimated in the study's analysis. It should not be presented as the change that every participant experienced. Keeping the comparison and measurement units visible helps preserve what the experiment actually found.

FMD was the primary endpoint

The primary outcome was brachial artery flow-mediated dilation, abbreviated as FMD. This measures endothelial function through an artery's widening in response to increased blood flow. In plain language, the study examined a specific aspect of blood-vessel responsiveness.

The researchers reported an adjusted between-group FMD difference of +2.9 percentage points at six months. The direction favored the supplement group. The unit matters: the finding was expressed in percentage points on the FMD measure.

Endothelial function is also studied outside supplement research. A systematic review of randomized aerobic-exercise trials examined this endpoint alongside other cardiovascular markers. That provides context for the kind of measurement used in STAMINA, not a comparison of the effects of exercise and this formulation.

The useful question is therefore specific: did this formulation affect the selected vascular endpoint under the study's conditions? That question is narrower than whether it changed aging as a whole. AgeAmaze's guide to interpreting trial endpoints and evidence provides a framework for keeping those questions separate.

Arterial stiffness and blood pressure also favored the supplement

The STAMINA researchers also reported an adjusted between-group difference of −1.18 m/s in PWV, the study's arterial-stiffness measurement. The corresponding difference in systolic blood pressure was −6.1 mmHg. Both results favored the supplement group at six months.

These findings broadened the vascular picture beyond the primary FMD outcome. They concerned different measurements, so they should remain separately identified rather than being combined into a single claim about rejuvenation. The clearest account preserves the endpoint attached to each result.

Blood lipids did not differ significantly between groups, according to the researchers. This is an important part of the overall result rather than a detail to leave out of an otherwise favorable summary. The trial's reported pattern was selective: several vascular measures favored the supplement while lipid levels did not show a significant between-group difference.

The risk score largely reflected the blood-pressure result

The estimated 10-year cardiovascular-risk score also shifted modestly in favor of the supplement group. The researchers said that difference was driven primarily by systolic blood pressure. Its interpretation therefore depends heavily on the blood-pressure finding already described.

The score should be read as an estimate rather than a separate observed health outcome. Presenting the blood-pressure difference and the risk-score difference as wholly independent evidence would overstate how much distinct information they provide. A careful summary explains their connection.

For readers interested in biological-age testing, this illustrates why the identity of a measurement matters as much as its direction. A favorable result needs to retain its original meaning as it moves from a paper into a headline. The broader challenge is connecting biomarker signals with meaningful health outcomes, rather than treating every favorable measurement as interchangeable evidence.

The design leaves important questions unresolved

MedicalXpress quoted Surrey cardiovascular-medicine professor Christian Heiss describing favorable vascular-biomarker changes. Surrey founding dean Juliet Wright called the findings a “proof of concept.” Those descriptions fit a study whose limitations remain central to its interpretation:

  • The primary analysis did not include everyone randomized. The main FMD analysis included 43 participants who completed the relevant assessments. Incomplete follow-up creates uncertainty about how well the analyzed group represents the full randomized group. The headline enrollment figure should not be mistaken for the number contributing to the primary result.
  • The study was small and conducted at a single centre. The authors said it was not designed to establish generalizability to the wider population. A result from one research setting needs confirmation beyond that setting before it supports a broad claim.
  • The participants represented a limited health profile. They were generally healthy adults who did not smoke. The findings therefore do not establish how the formulation would perform in people with cardiovascular disease or other higher-risk groups.
  • Clinical cardiovascular events were not the outcomes tested. The trial measured intermediate vascular markers rather than heart attacks or strokes. The authors said the study was not powered to determine effects on clinical events. The estimated risk score is not a count of events prevented.
  • The experiment did not isolate ingredients or establish a mechanism. Researchers tested the formulation as a whole. They did not determine which components contributed to the findings or whether ingredients acted independently or together. Dose-response relationships were also not assessed.
  • Adherence and assessment timing add uncertainty. Compliance was monitored through participant diaries rather than an objective measure. The authors also noted that the six-month assessment did not follow a formal pharmacokinetic washout. These details matter when interpreting exposure and claims about lasting effects.
  • Company support needs to remain visible. The study had company support. MedicalXpress reported that NOVOS research and development director Diogo Barardo viewed the results as consistent with the company's hypothesis about addressing multiple aging-related processes. That is a company-affiliated interpretation rather than independent confirmation of that hypothesis.

For readers evaluating a supplement claim, the practical task is to match the wording to the measured outcome. Look for the actual endpoint and the population studied before considering the broader interpretation. A claim about FMD should remain a claim about FMD unless additional evidence supports a wider conclusion.

The same discipline applies when comparing future studies. Ask whether they repeat the original endpoint or test a more direct health outcome. These are different contributions to the evidence base, and both should be described accurately. Personal decisions about supplements or cardiovascular care belong in a discussion with a qualified healthcare professional rather than being inferred from this experiment alone.

Independent replication is the next test

The next logical step is independent replication in larger and more diverse populations, followed by longer-term research testing whether the vascular changes translate into meaningful clinical benefits.

How AgeAmaze helps

Following STAMINA means assessing how later supplement claims relate to the measurements behind them, a task AgeAmaze supports with clear explanations of longevity research. When vascular findings are recast as biological-age benefits, AgeAmaze helps research-minded adults distinguish established evidence from preliminary interpretations without turning emerging interventions into promises.

Read the research

Sources

  1. Supplement targeting aging processes shows potential to improve markers of blood vessel health
  2. Impact of Aerobic Exercise on Endothelial Function and Other Cardiovascular Disease Markers in Health and Disease: A Systematic Review and Meta-analysis with Meta-regression of Randomized Controlled Trials

Stay current with research on aging biology, biomarkers, nutrition, therapeutics, peptides and longevity technology. AgeAmaze reports what the evidence shows, where uncertainty remains and which claims still need stronger data.

FacebookInstagramYouTubeXPinterest

Continue reading

Long-Follow-Up Study Links Gum Disease to Older Epigenetic-Age Readings
November 22, 2026
Biological Age & Testing

Long-Follow-Up Study Links Gum Disease to Older Epigenetic-Age Readings

read article
Fasting-Mimicking Diet Research: Biomarkers Before Lifespan Claims
November 21, 2026
Cellular Health & Metabolism

Fasting-Mimicking Diet Research: Biomarkers Before Lifespan Claims

read article
Senolytics vs. Senomorphics: Different Actions, Different Evidence
November 21, 2026
Peptides & Emerging Therapies

Senolytics vs. Senomorphics: Different Actions, Different Evidence

read article
keep reading

Longevity research changes faster than the headlines

Follow AgeAmaze for careful reporting on what longevity science can show today and what still needs stronger evidence.

read the Blog
Woman reading health research at a table in natural daylight